EUVIMEDObjevte EUVIMED
Open access · CC BY 4.0

An Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer

Rongkang Li, Anguo Zhao, Qi Zhuang, Lei Peng iD, Rui Liang iD, Jiadong Zhao, Yang Liu, Dashi Deng, Peng Yu, Xiqi Peng iD, Shaohua Zhang iD, Song Wu

Advanced Science · 2026-11 · 13 (62)

DOI: 10.1002/advs.77241 ↗

At a glance

Journal article in Advanced Science, published online on 2026-08-17. Written by Rongkang Li and 11 co-authors. Institution: Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Major MEDLINE topics: Urinary Bladder Neoplasms, Immunotherapy, Doxorubicin, Probiotics. Cited 1 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shenzhen Medical Research Fund, National Natural Science Foundation of China, Sanming Project of Medicine in Shenzhen.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Bladder cancer (BC) is a highly recurrent urinary malignancy for which current intravesical immunotherapy and chemotherapy are limited by insufficient efficacy, toxicity, excessive inflammation, and drug resistance. The probiotic Akkermansia muciniphila (AKK), known for its ability to modulate immune responses and suppress pathological inflammation, provides a promising immunomodulatory component to address these limitations. Here, an intravesical bacteria‐based chemo‐immunotherapeutic platform is developed by loading doxorubicin (DOX) onto pasteurized AKK modified with F127, yielding AKK‐F127/DOX (AF/D). Compared with free DOX, AF/D more effectively inhibits bladder cancer cell proliferation, migration, and invasion, while inducing apoptosis, ferroptosis, immunogenic cell death, and suppressing the NF‐κB inflammatory pathway. AF/D also promotes dendritic‐cell maturation, pro‐inflammatory cytokine secretion, M1‐like macrophage polarization, antigen cross‐presentation, and tumor‐specific CD8 + T‐cell priming. In orthotopic bladder cancer models, intravesical AF/D shows superior antitumor efficacy and survival benefits over single‐agent treatments, remodels the local immune microenvironment, enhances systemic antigen‐specific CD8 + T‐cell responses in the spleen, and maintains a favorable safety profile. These findings establish AF/D as a promising intravesical chemo‐immunotherapeutic strategy for bladder cancer.

Subjects

MeSH terms (MEDLINE)

Urinary Bladder NeoplasmsImmunotherapyDoxorubicinProbioticsAnimalsHumansMiceAdministration, IntravesicalFemaleCell Line, TumorAkkermansia

Author keywords

akkermansia muciniphilabladder cancerchemo‐immunotherapyferroptosisintravesical therapy

Substances

Doxorubicin

Authors and institutions

  • Department of Urology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Urology, South China Hospital, Medical School, Shenzhen University, Shenzhen, China.
  • Department of Urology, The Fourth Affiliated Hospital of Soochow University, Medical Center of Soochow University, Suzhou Dushu Lake Hospital, Suzhou, China.
  • Guangdong Key Laboratory for Biomedical Measurements and Ultrasound Imaging, National-Regional Key Technology Engineering Laboratory for Medical Ultrasound, School of Biomedical Engineering, Shenzhen University Medical…

ORCID profiles: Lei Peng, Rui Liang, Xiqi Peng, Shaohua Zhang

Funding

  • Shenzhen Medical Research Fund
  • National Natural Science Foundation of China
  • Sanming Project of Medicine in Shenzhen
  • Shenzhen Science and Technology Innovation Commission
  • National Key Research and Development Program of China
  • Shenzhen Science and Technology Program
  • Shenzhen Engineering Research Center
  • Project funded by China Postdoctoral Science Foundation

Cite

APA

Li, R., Zhao, A., Zhuang, Q., Peng, L., Liang, R., Zhao, J., Liu, Y., Deng, D., Yu, P., Peng, X., Zhang, S., & Wu, S. (2026). An Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer. Advanced Science, 13(62). https://doi.org/10.1002/advs.77241

Vancouver

Li R, Zhao A, Zhuang Q, Peng L, Liang R, Zhao J, et al. An Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer. Advanced Science. 2026;13(62). doi:10.1002/advs.77241

BibTeX
@article{Li2026,
  author = {Li, Rongkang and Zhao, Anguo and Zhuang, Qi and Peng, Lei and Liang, Rui and Zhao, Jiadong and Liu, Yang and Deng, Dashi and Yu, Peng and Peng, Xiqi and Zhang, Shaohua and Wu, Song},
  title = {An Intravesical Akkermansia muciniphila ‐Based Chemo‐Immunotherapeutic Platform for Bladder Cancer},
  journal = {Advanced Science},
  year = {2026},
  volume = {13},
  number = {62},
  doi = {10.1002/advs.77241}
}
Start for free →